Home > Boards > US OTC > Medical - Equipment >

Positron Corporation (POSC)

Add POSC Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/7/2018 4:38:58 PM - Followers: 165 - Board type: Free - Posts Today: 0


Symbol: OTC: POSC

Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography (PET). Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD), a leading cause of death in the United States. Positron’s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine.

Positron, a pioneer in nuclear cardiology for over 30 years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron’s approach is to provide nuclear cardiologists an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source.  Positron's business approach will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.

Positron Corporation is a publicly listed company. Shares of common stock of Positron Corporation are currently trading on the National Association of Securities Dealers, Inc.'s under the symbol POSC.

Key Business Components 
PET Imaging System and Services
The Attrius®, dedicated PET imaging system, is optimized for cardiology. Positron's Attrius provides customers with state-of-the-art imaging technology for the diagnosis, treatment and prevention of cardiovascular disease. The Attrius is the only dedicated PET scanner in the world and was awarded Frost & Sullivan's Most Innovative Medical Device of the Year award as "the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology."  Positron complements its technology by offering comprehensive world-class clinical, technical and service support through their PosiStar™ customer care plan.

Financing Solutions
Positron provides customers with a variety of financing solutions for its full solutions model designed to minimize any barriers to entry, thus accelerating the expansion of cardiac PET and further securing Positron's current and future position in the market.

Market Opportunities
Nuclear medicine helps in the diagnosis, management and prevention of patients with cardiovascular disease (CVD). Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease; conditions that are responsible for almost all heart attacks. Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011).  Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, and indirect costs (due to lost productivity) will rise from $172 billion in 2010 to $276 billion in 2030.
Positron Emission Tomography (PET)
PET is a more advanced and accurate technology. In cardiac perfusion imaging, PET scanners, in particular Positron's Attrius, have superior sensitivity and specificity compared to that of SPECT cameras. PET also produces less radiation exposure and is capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and excellent clinical outcomes compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48: 1069-1076).  
The cardiac PET equipment market is much smaller than SPECT but has seen significant annual growth, of 25-30%, during the last decade. For many years, a major constraint for this market has been the high cost of PET and PET/CT scanners for cardiac studies. Positron has managed to reduce the buyers' barrier to entry by bringing to market the Attrius; the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems that have a comparable performance of cardiac studies but have a 200% to 300% higher price, in relation to the Attrius. These same PET/CT systems also possess attributes not optimized or conducive for cardiac imaging. 

Attrius is the only FDA approved new dedicated PET scanner optimized for cardiac imaging.

The Attrius provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases for nuclear cardiologists.  This innovative software includes coronary artery overlay display, open architecture for new protocol development, customization and motion correction and the ability to monitor therapy. The Attrius is targeted for cardiac clinics and hospitals and is designed to meet the performance, budget and space constraints of the most demanding cardiologists.
Attrius was named the "Most Innovative Device of 2010" by the renowned business research and consulting firm Frost & Sullivan.

Positron achieved significant advancements with the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas.
The CFR software, a clear differentiator for PET imaging compared to SPECT, was developed by a leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.

Positron is PET.

Company Website:

Share Structure
October 2017

Authorized Shares: 400,000,000 Common Shares
Outstanding Shares: 14,275,979  Common Shares (fully diluted)
Approximate Float: 4,000,000 Common Shares

Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

DISCLAIMER: The Moderator owns a position in POSC. He has not been compensated by any party for any post regarding POSC, and has never been compensated by any company nor any party for any post regarding any stock. Moderator may buy, hold, or sell his position at any time without warning to any party. Posts are not meant as a solicitation to buy, sell, or hold any position in POSC, nor any other stock. Moderator may be buying, or selling, stock in POSC as he is posting. There is no guarantee that the Moderator may not immediately eliminate his position on any day at any time during market hours. Do not buy, hold, or sell based upon any post regarding this stock, or any other equity. Do your own Due Diligence, and buy, sell, or hold based upon your own due diligence.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#19300   Mike Adamle Project Concussion Legacy Foundation Medtrade77 02/07/18 04:38:58 PM
#19299   PET used in CTE studies. Whole new frontier for Medtrade77 02/07/18 04:31:36 PM
#19298   2017 Clean up 2018 Turn around Get on board! Medtrade77 12/31/17 11:18:11 AM
#19297   Someone must still have shares Medtrade77 11/02/17 10:37:27 AM
#19296   No offers just bids Anything new? Medtrade77 11/02/17 10:36:42 AM
#19295   Actual bids in this forgotten name. That's kind Medtrade77 11/01/17 01:14:19 PM
#19294   Something must be in works. No interest for Medtrade77 10/12/17 02:04:55 PM
#19293   $POSC CURRENT SHARE STRUCTURE UPDATED 10/5/17 aapples1992 10/10/17 11:33:10 PM
#19292  Restored We as shareholders need to take control guys!! aapples1992 10/10/17 11:29:08 PM
#19291   POSC update would be nice! aapples1992 10/10/17 11:27:18 PM
#19290   Yes, I agree they should think about putting aapples1992 10/10/17 11:25:30 PM
#19289   News would be nice for a change. They are Medtrade77 09/27/17 02:41:44 PM
#19288   Good question! RealnessNYC 09/26/17 11:10:14 AM
#19287   What is going on here. jerry57 09/26/17 10:28:50 AM
#19286   True Must all stem from the reorganization. While operating Medtrade77 09/20/17 10:25:50 AM
#19285   POSC is severely delinquent in filing the company's Renee 09/19/17 04:43:39 PM
#19284   Finally some good news. Time to move forward Medtrade77 09/11/17 09:20:57 AM
#19283   Shareholders need to go run this company. Their Medtrade77 09/08/17 03:58:13 PM
#19282   Actual volume this week. Someone picking up shares is Medtrade77 07/14/17 05:48:28 PM
#19281   POSC defended its case and won. Finally. Turn around? Medtrade77 06/13/17 11:43:13 AM
#19280   They have been too quite. I assume they are Medtrade77 05/08/17 10:02:00 AM
#19279   Now's a great time to load the boat aapples1992 05/06/17 10:12:14 PM
#19278   I agree this should get going again soon. aapples1992 05/06/17 10:10:37 PM
#19277   All these small niche players should rise with Medtrade77 05/05/17 11:03:14 AM
#19276   Imaging high priority with insurance carriers. Medtrade77 05/05/17 10:59:59 AM
#19275   PET headlining at SNM in June Medtrade77 05/05/17 10:58:34 AM
#19274   Radioisotopes remain the issue. Medtrade77 05/05/17 10:36:48 AM
#19273   Bracco adds customers when existing customer discontinues. Zero Medtrade77 04/29/17 10:20:38 AM
#19272   PET Imaging Centers openings in same month. Movement Medtrade77 04/29/17 10:01:41 AM
#19271   Results from reorganization? Any longs care to shed Medtrade77 04/29/17 09:57:19 AM
#19270   Anyone following this story ? Medtrade77 03/31/17 07:24:44 PM
#19269   Anyone following this story anymore Medtrade77 03/31/17 07:23:42 PM
#19268   Positron rid itself of all that pharma nonsense Medtrade77 12/27/16 04:47:11 PM
#19267   Didn't he already complete his country club ' plinter1 07/22/16 08:25:57 AM
#19266   Rooney's sentence includes watching the POSC stock chart bpatient 07/21/16 04:33:39 PM
#19265   $2 trade all day what is the point? plinter1 07/19/16 07:19:22 PM
#19263   Maybe nobody is surprised.. junkHustler 05/25/16 05:17:47 PM
#19262   Surprised no one has commented on the bankruptcy filing plinter1 05/25/16 05:06:17 PM
#19261   All is quiet, with this company. I still stockslueth 04/26/16 03:32:37 PM
#19255   What a piece of crap mudslog 03/25/16 09:46:49 PM
#19254   More not so great news.. junkHustler 02/22/16 06:56:38 PM
#19252   I can't believe there are people still dreaming dcool1 12/16/15 04:49:30 PM
#19251   I agree ipotter aapples1992 11/25/15 08:44:57 PM
#19250   I agree ipotter aapples1992 11/25/15 08:44:57 PM
#19249   70mev magnet is on at Zevacor's facility. ipotter 11/24/15 01:40:58 PM
#19248   The group pushing the involuntary bankruptcy is Manhattan Jacker 11/24/15 10:54:48 AM
#19247   The only thing that makes ZERO sense is junkHustler 11/24/15 10:26:50 AM
#19246   I had order in for .10 went to aapples1992 11/17/15 09:31:20 PM
#19245   The higher bids were ignored completely. ipotter 11/17/15 01:16:09 PM
#19244   Yikes. Day Low 0.0151 0.18 (-90.00%) junkHustler 11/17/15 11:38:14 AM